FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Res Commun / Tenogenic induction of equine mesenchymal stem cells by mean...
Veterinary research communications2016; 40(1); 39-48; doi: 10.1007/s11259-016-9652-y

Tenogenic induction of equine mesenchymal stem cells by means of growth factors and low-level laser technology.

Abstract: Tendons regenerate poorly due to a dense extracellular matrix and low cellularity. Cellular therapies aim to improve tendon repair using mesenchymal stem cells and tenocytes; however, a current limitation is the low proliferative potential of tenocytes in cases of severe trauma. The purpose of this study was to develop a method useful in veterinary medicine to improve the differentiation of Peripheral Blood equine mesenchymal stem cells (PB-MSCs) into tenocytes. PB-MSCs were used to study the effects of the addition of some growth factors (GFs) as TGFβ3 (transforming growth factor), EGF2 (Epidermal growth factor), bFGF2 (Fibroblast growth factor) and IGF-1 (insulin-like growth factor) in presence or without Low Level Laser Technology (LLLT) on the mRNA expression levels of genes important in the tenogenic induction as Early Growth Response Protein-1 (EGR1), Tenascin (TNC) and Decorin (DCN). The singular addition of GFs did not show any influence on the mRNA expression of tenogenic genes whereas the specific combinations that arrested cell proliferation in favour of differentiation were the following: bFGF2 + TGFβ3 and bFGF2 + TGFβ3 + LLLT. Indeed, the supplement of bFGF2 and TGFβ3 significantly upregulated the expression of Early Growth Response Protein-1 and Decorin, while the use of LLLT induced a significant increase of Tenascin C levels. In conclusion, the present study might furnish significant suggestions for developing an efficient approach for tenocyte induction since the external administration of bFGF2 and TGFβ3, along with LLLT, influences the differentiation of PB-MSCs towards the tenogenic fate.
Get Full Text
Publication Date: 2016-01-13 PubMed ID: 26757735DOI: 10.1007/s11259-016-9652-yGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article investigates a new method to improve the healing of horse tendon injuries. By promoting the differentiation of horse mesenchymal stem cells into tenocytes (tendon cells) through the use of growth factors and low-level laser technology, the researchers aim to overcome the issues commonly faced in tendon regeneration.

Objective of the Study

  • The study aims to develop a more effective method for tendon repair, particularly in cases of severe trauma. This method, targeted for use in veterinary medicine, involves encouraging the differentiation of Peripheral Blood equine mesenchymal stem cells (PB-MSCs) into tenocytes via the addition of various growth factors and the application of low-level laser technology.

Methodology

  • The researchers tested the effects of various growth factors – TGFβ3 (transforming growth factor), EGF2 (Epidermal growth factor), bFGF2 (Fibroblast growth factor), and IGF-1 (insulin-like growth factor) on the PB-MSCs, both with and without the application of Low-Level Laser Technology (LLLT).
  • They examined the influence of these factors on mRNA expression levels of certain genes – Early Growth Response Protein-1 (EGR1), Tenascin (TNC), and Decorin (DCN) – that play a critical role in tenogenic induction, or the formation and development of tenocytes.

Findings

  • The study found that the singular addition of any one of the tested growth factors did not significantly influence the mRNA expression of these tenogenic genes.
  • However, specific combinations of these factors, particularly bFGF2 + TGFβ3 and bFGF2 + TGFβ3 + LLLT, significantly inhibited cell proliferation in favor of differentiation.
  • The addition of bFGF2 and TGFβ3 significantly boosted the expression of Early Growth Response Protein-1 and Decorin.
  • Furthermore, the use of Low-Level Laser Technology resulted in a significant surge in Tenascin C levels.

Conclusions

  • The findings of this study suggest that an effective approach for inducing tenocyte formation and promoting tendon repair may involve externally administering bFGF2 and TGFβ3 together with applying Low-Level Laser Technology.
  • This triple method successfully influences the differentiation of PPB-MSCs towards tenogenesis, implying its potential for practical application in veterinary medicine for better tendon repair processes, particularly in cases of severe trauma.

Cite This Article

APA
Gomiero C, Bertolutti G, Martinello T, Van Bruaene N, Broeckx SY, Patruno M, Spaas JH. (2016). Tenogenic induction of equine mesenchymal stem cells by means of growth factors and low-level laser technology. Vet Res Commun, 40(1), 39-48. https://doi.org/10.1007/s11259-016-9652-y

Publication

Veterinary research communications
ISSN: 1573-7446
NlmUniqueID: 8100520
Country: Switzerland
Language: English
Volume: 40
Issue: 1
Pages: 39-48

Researcher Affiliations

Gomiero, Chiara
  • Department of Comparative Biomedicine and Food Science, University of Padova, Viale dell'Università 16, Legnaro, 35020, Padova, Italy.
Bertolutti, Giulia
  • Department of Comparative Biomedicine and Food Science, University of Padova, Viale dell'Università 16, Legnaro, 35020, Padova, Italy.
Martinello, Tiziana
  • Department of Comparative Biomedicine and Food Science, University of Padova, Viale dell'Università 16, Legnaro, 35020, Padova, Italy.
Van Bruaene, Nathalie
  • Global Stem Cell Technology-ANACURA Group, Noorwegenstraat 4, 9940, Evergem, Belgium.
Broeckx, Sarah Y
  • Global Stem Cell Technology-ANACURA Group, Noorwegenstraat 4, 9940, Evergem, Belgium.
Patruno, Marco
  • Department of Comparative Biomedicine and Food Science, University of Padova, Viale dell'Università 16, Legnaro, 35020, Padova, Italy. marco.pat@unipd.it.
Spaas, Jan H
  • Global Stem Cell Technology-ANACURA Group, Noorwegenstraat 4, 9940, Evergem, Belgium.

MeSH Terms

  • Animals
  • Cell Differentiation / drug effects
  • Cell Proliferation
  • Cells, Cultured
  • Decorin / genetics
  • Early Growth Response Protein 1 / genetics
  • Extracellular Matrix Proteins / genetics
  • Gene Expression Regulation / drug effects
  • Horses
  • Intercellular Signaling Peptides and Proteins / pharmacology
  • Low-Level Light Therapy
  • Mesenchymal Stem Cells / cytology
  • Mesenchymal Stem Cells / drug effects
  • Tendon Injuries / therapy
  • Tendon Injuries / veterinary
  • Tendons / cytology

References

This article includes 66 references
  1. Stem Cells. 2006 Jun;24(6):1613-9
    pubmed: 16769763
  2. J Orthop Res. 2013 Feb;31(2):306-14
    pubmed: 22893604
  3. Equine Vet J. 2015 May;47(3):319-25
    pubmed: 24773596
  4. Biochem Biophys Res Commun. 2007 Oct 19;362(2):347-53
    pubmed: 17719011
  5. Curr Stem Cell Res Ther. 2014;9(6):452-7
    pubmed: 24548143
  6. J Biophotonics. 2015 Oct;8(10 ):795-803
    pubmed: 25411997
  7. Lasers Surg Med. 2006 Jan;38(1):74-83
    pubmed: 16444694
  8. PLoS One. 2014 Jul 23;9(7):e102993
    pubmed: 25054279
  9. PLoS One. 2013 Sep 25;8(9):e75697
    pubmed: 24086616
  10. J Biol Chem. 2011 Feb 18;286(7):5855-67
    pubmed: 21173153
  11. Stem Cell Res Ther. 2014 Feb 21;5(1):25
    pubmed: 24559797
  12. Vet J. 2013 Jan;195(1):107-13
    pubmed: 22717781
  13. Matrix Biol. 2013 Jan;32(1):3-13
    pubmed: 23178232
  14. Clin Orthop Relat Res. 2002 Jul;(400):174-83
    pubmed: 12072760
  15. Mol Med Rep. 2013 Nov;8(5):1323-8
    pubmed: 24008926
  16. Nat Clin Pract Rheumatol. 2008 Feb;4(2):82-9
    pubmed: 18235537
  17. Sports Med. 2003;33(5):381-94
    pubmed: 12696985
  18. Lasers Med Sci. 2015 Jan;30(1):263-72
    pubmed: 25231827
  19. Mol Biosyst. 2013 Jun;9(6):1147-61
    pubmed: 23364335
  20. Vet Med Int. 2010;2010:250978
    pubmed: 20445779
  21. J Hand Surg Am. 2002 Jul;27(4):615-20
    pubmed: 12132085
  22. Ann Plast Surg. 2004 Oct;53(4):393-7
    pubmed: 15385778
  23. J Dermatol Sci. 2000 Dec;24 Suppl 1:S70-7
    pubmed: 11137399
  24. J Bone Joint Surg Br. 2000 Sep;82(7):1054-8
    pubmed: 11041601
  25. Lasers Med Sci. 2013 Feb;28(2):543-50
    pubmed: 22552925
  26. Am J Vet Res. 2010 Oct;71(10):1237-45
    pubmed: 20919913
  27. PLoS One. 2014 Jan 20;9(1):e85917
    pubmed: 24465787
  28. J Vis Exp. 2013 Sep 26;(79):e50585
    pubmed: 24121366
  29. J Mater Sci Mater Med. 2013 Jan;24(1):211-20
    pubmed: 23090834
  30. J Cell Biochem. 2006 Aug 15;98(6):1436-49
    pubmed: 16518859
  31. Knee Surg Sports Traumatol Arthrosc. 2012 Jan;20(1):48-61
    pubmed: 21773828
  32. Int Orthop. 2007 Dec;31(6):791-7
    pubmed: 17634943
  33. Tissue Eng Part A. 2014 Oct;20(19-20):2604-13
    pubmed: 24628376
  34. Lasers Med Sci. 2011 Jan;26(1):85-94
    pubmed: 20737183
  35. Front Vet Sci. 2015 Oct 22;2:49
    pubmed: 26664976
  36. Plast Reconstr Surg. 1991 Aug;88(2):189-94; discussion 195-6
    pubmed: 1852809
  37. Cell Physiol Biochem. 2015 ;35(2):699-709
    pubmed: 25592085
  38. Int J Mol Sci. 2014 Sep 15;15(9):16257-69
    pubmed: 25226535
  39. Stem Cells. 2008 Jun;26(6):1598-608
    pubmed: 18356575
  40. Tissue Eng Part B Rev. 2011 Jun;17(3):165-76
    pubmed: 21314435
  41. Sports Med. 2012 Oct 1;42(10):871-90
    pubmed: 22963225
  42. Res Vet Sci. 2011 Aug;91(1):18-24
    pubmed: 20732703
  43. Nat Med. 2007 Oct;13(10 ):1219-27
    pubmed: 17828274
  44. Scientifica (Cairo). 2014;2014:874065
    pubmed: 25332839
  45. Stem Cells. 2006 Mar;24(3):686-95
    pubmed: 16150920
  46. Wound Repair Regen. 2014 Jan-Feb;22(1):111-8
    pubmed: 24393159
  47. Cytotherapy. 2014 May;16(5):662-73
    pubmed: 24095259
  48. Photomed Laser Surg. 2015 Mar;33(3):154-63
    pubmed: 25751667
  49. PLoS One. 2013 Dec 30;8(12):e83734
    pubmed: 24386267
  50. Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):325-34
    pubmed: 22697064
  51. Biol Res Nurs. 2014 Apr;16(2):191-6
    pubmed: 23559459
  52. Stem Cells Dev. 2012 Mar 20;21(5):790-800
    pubmed: 21627568
  53. Scand J Med Sci Sports. 2013 Oct;23(5):614-9
    pubmed: 22288768
  54. Cell Tissue Res. 2012 Jan 28;347(3):677-688
    pubmed: 22287044
  55. Dermatol Surg. 2005 Mar;31(3):334-40
    pubmed: 15841638
  56. Am J Vet Res. 2012 Jan;73(1):153-61
    pubmed: 22204302
  57. Histol Histopathol. 2014 Apr;29(4):417-22
    pubmed: 24203578
  58. Cytotherapy. 2015 Feb;17(2):215-23
    pubmed: 25484309
  59. Tissue Eng Part C Methods. 2010 Aug;16(4):771-81
    pubmed: 19839741
  60. Curr Stem Cell Res Ther. 2014;9(6):497-503
    pubmed: 25175766
  61. Muscles Ligaments Tendons J. 2014 Jul 14;4(2):245-55
    pubmed: 25332943
  62. J Orthop Res. 2011 Sep;29(9):1351-60
    pubmed: 21437969
  63. Clin Orthop Relat Res. 2015 May;473(5):1635-43
    pubmed: 25690170
  64. Histol Histopathol. 2009 Oct;24(10 ):1207-11
    pubmed: 19688689
  65. Differentiation. 2008 Feb;76(2):118-29
    pubmed: 17697129
  66. Exp Eye Res. 2015 Jun;135:118-26
    pubmed: 25708868
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.